Exagen Inc.XGNNASDAQ
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank58
3Y CAGR-23.5%
5Y CAGR-23.9%
Studio
Year-over-Year Change

Year-over-year research & development expense growth

3Y CAGR
-23.5%/yr
vs -0.4%/yr prior
5Y CAGR
-23.9%/yr
Consistent
Acceleration
-23.1pp
Decelerating
Percentile
P58
Within normal range
vs 5Y Ago
0.3x
Contraction
Streak
2 yr
Consecutive growthRecovering
PeriodValue
202516.35%
202410.48%
2023-50.74%
202236.47%
2021102.83%
202063.97%
20192.40%
201837.01%
20170.00%
20156.22%